OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Krop on the Efficacy and Tolerability of SHR-A1811 in Advanced HER2+ Breast Cancer

January 20th 2025

Ian Krop, MD, PhD, discusses SHR-A1811, a third-generation antibody-drug conjugate for HER2-positive breast cancer.

Dr Davila on CD19 CAR T-Cell Therapy Resistance in Large B-Cell Lymphoma

January 20th 2025

Marco Davila, MD, PhD, explains the role of intrinsic tumor drivers in CD19 CAR T-cell therapy resistance in aggressive large B-cell lymphoma.

Dr Mowery on Pembrolizumab Plus Radiation Therapy and Surgery in Soft Tissue Sarcoma

January 20th 2025

Yvonne Mowery, MD, PhD, discusses the SU2C-SARC032 trial of pembrolizumab plus radiotherapy followed by surgery in soft tissue sarcoma.

Dr Werutsky on the Effects of HER2-Low Breast Cancer Subtype on Treatment Outcomes

January 17th 2025

Gustavo Werutsky, MD, PhD, discusses an exploratory analysis that outlined associations between HER2-low breast cancer subtype and clinical outcomes.

Dr Kalinka on Frontline BMS-986012 Plus Nivolumab and Chemotherapy in ES-SCLC

January 17th 2025

Ewa Kalinka, MD, PhD, discusses interim phase 2 data with frontline BMS-986012 plus nivolumab and chemotherapy in extensive-stage small cell lung cancer.

Dr Garje on Unmet Needs in Small Cell Bladder Cancer

January 17th 2025

Rohan Garje, MD, discusses the unmet needs for patients with small cell bladder cancer.

Dr Parikh on the Clinical Implications of Molecular Testing on mCRC Management

January 17th 2025

Aparna Parikh, MD, discusses the importance of upfront molecular testing in patients with metastatic colorectal cancer.

Dr Phillips on the Rationale of Evaluating Glofitamab in R/R Mantle Cell Lymphoma

January 17th 2025

Tycel Phillips, MD, MPH, discusses the rationale of the phase 1/2 NP30179 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

Dr Baljevic on Selinexor Plus Pomalidomide/Dexamethasone in R/R Myeloma

January 17th 2025

Muhamed Baljevic, MD, discusses the efficacy and safety of selinexor in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr Al Malki on the Potential Use of TSC-100 and TSC-101 After Transplant in AML, ALL, and MDS

January 17th 2025

Monzr M. Al Malki, MD, discusses the potential use of TSC-100 and TSC-101 following allogeneic stem cell transplant in patients with AML, ALL or MDS.

Dr Daver on the Potential Role for Menin Inhibitors in Frontline AML

January 17th 2025

Naval G. Daver, MD, discusses the potential role for menin inhibitors in the frontline treatment of patients with acute myeloid leukemia.

Dr Badami on the Optimal Selection of Second-Line TKIs in ccRCC

January 16th 2025

Ami Umesh Badami, MD, discusses clinical research that has informed treatment selection in the second-line clear cell renal cell carcinoma setting.

Dr Philip on Considerations for Selecting First-Line Treatment in Newly Diagnosed, Low-Risk GI NETs

January 16th 2025

Philip Philip, MD, discusses considerations for selecting first-line treatment for newly diagnosed, low-risk gastrointestinal neuroendocrine tumors.

Dr Nathanson on BRCA1/2 Reversion Mutations in Response to Therapy in Breast Cancer

January 16th 2025

Katherine L. Nathanson, MD, discusses the identification of reversion mutations in BRCA1/2 in response to therapy among patients with breast cancer.

Dr Barata on Improved Clinical Outcomes with Darolutamide in mHSPC

January 16th 2025

Pedro Barata, MD, discusses improved clinical outcomes with darolutamide in metastatic hormone-sensitive prostate cancer.

Dr Hunter on the Development of Targeted Approaches Beyond JAK Inhibition in Myelofibrosis

January 16th 2025

Anthony M. Hunter, MD, discusses the development of, and future roles for JAK, BET, and BCL2/BCL-XL inhibitors in myelofibrosis.

Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm

January 16th 2025

Thomas Westbrook, MD, discusses the non–clear cell renal cell carcinoma research that informs his clinical practice.

Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

January 16th 2025

John K. Lee, MD, PhD, discusses the EV-302 trial of frontline enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Dr Kim on The Efficacy and Safety of Odronextamab in R/R MZL

January 15th 2025

Tae Min Kim, MD, PhD, discusses the efficacy of odronextamab monotherapy in patients with relapsed/refractory marginal zone lymphoma.

Dr Goldsberry on the Risk of Secondary Malignancies With PARP Inhibitors in Ovarian Cancer

January 15th 2025

Whitney Goldsberry, MD, discusses the potential risk of secondary malignancies in patients with ovarian cancer receiving PARP inhibitors.